News Agency
Men's Weekly

Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023

  • Written by PR Newswire

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all patients treated in the expansion cohort

PRINCETON, N.J. and SUZHOU, China, Oct. 23, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical-stage...

Read more: Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line...

How Labour Hire Supports Sydney and Gold Coast Businesses

Labour hire has transformed from a simple stopgap measure into one of the most strategically valuable workforce solutions for businesses right across Sydney and the Gold Coast. As various industries grow, adapt to punishing seasonal demand, or suddenly find themselves... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion